LivingGLP1
Study S001509

An Open-label, Sequential Study to Evaluate the Pharmacokinetics of Digoxin When Coadministered With Albiglutide in Healthy Adult Subjects

Registration

Registration
NCT01147718
Study type
INTERVENTIONAL
Phase
PHASE1
Masking
NONE
Status
COMPLETED
Enrollment
30
Start
2010-06-11
Primary completion
2010-11-29
Lead sponsor
GlaxoSmithKline
Conditions
Diabetes Mellitus, Type 2
Interventions
BIOLOGICAL:digoxin plus albiglutide
Results posted
FALSE
Individual participant data sharing
YES

Registered primary outcomes

  • The pharmacokinetic parameters of digoxin with and without albiglutide [38 days]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0018591Clinical pharmacology of albiglutide, a GLP-1 receptor agonist.
Young MA, Postgraduate medicine
2014Other trialPMID 25387217DOIcites ClinicalTrials.gov:NCT01147718; registry reference DERIVED:25387217
R0022625Effects of multiple doses of albiglutide on the pharmacokinetics, pharmacodynamics, and safety of digoxin, warfarin, or a low-dose oral contraceptive.
Bush M, Postgraduate medicine
2012Other trialPMID 23322139DOIregistry reference BACKGROUND:23322139